104 related articles for article (PubMed ID: 1842600)
1. Urinary succinylacetone presence and delta-aminolaevulinic acid excretion in patients with type I tyrosinaemia during treatment.
Pronicka E; Mielniczuk Z; Rowińska E; Ksiazyk J; Szczygielska-Kozak M; Wieczorek E; Kulczycka H
Mater Med Pol; 1991; 23(2):136-8. PubMed ID: 1842600
[TBL] [Abstract][Full Text] [Related]
2. Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.
Schierbeek H; Beukeveld GJ; van Faassen H; van Spronsen FJ; Bijsterveld K; Venekamp-Hoolsema EE; Wolthers BG; Smit GP
J Inherit Metab Dis; 1993; 16(6):1034-40. PubMed ID: 8127053
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.
Christensen E; Jacobsen BB; Gregersen N; Hjeds H; Pedersen JB; Brandt NJ; Baekmark UB
Clin Chim Acta; 1981 Nov; 116(3):331-41. PubMed ID: 7296896
[TBL] [Abstract][Full Text] [Related]
4. Identification of 4,6-dioxoheptanoic acid (succinylacetone), 3,5-dioxooctanedioic acid (succinylacetoacetate) and 4-Oxo-6-hydroxyheptanoic acid in the urine from patients with hereditary tyrosinemia.
Lindblad B; Steen G
Biomed Mass Spectrom; 1982 Oct; 9(10):419-24. PubMed ID: 7171740
[TBL] [Abstract][Full Text] [Related]
5. Tyrosinaemia type Ia without excess of urinary succinylacetone.
Biasucci G; Giuffré B; La Grutta S; Riva E
J Inherit Metab Dis; 1993; 16(6):1056-7. PubMed ID: 8127063
[No Abstract] [Full Text] [Related]
6. Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.
Bain MD; Purkiss P; Jones M; Bingham P; Stacey TE; Chalmers RA
Eur J Pediatr; 1990 Jun; 149(9):637-9. PubMed ID: 2373116
[TBL] [Abstract][Full Text] [Related]
7. Liver transplantation in nine Spanish patients with tyrosinaemia type I.
Pérez-Cerdá C; Merinero B; Sanz P; Castro M; Gangoiti J; García MJ; Díaz M; Medina E; Ugarte M
J Inherit Metab Dis; 1995; 18(2):119-22. PubMed ID: 7564224
[No Abstract] [Full Text] [Related]
8. A case of tyrosinaemia type I with normal level of succinylacetone in the amniotic fluid.
Grenier A; Cederbaum S; Laberge C; Gagné R; Jakobs C; Tanguay RM
Prenat Diagn; 1996 Mar; 16(3):239-42. PubMed ID: 8710777
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
10. [Surgical and metabolic aspects of liver transplantation for tyrosinemia].
Bruneau N; St-Vil D; Luks FI; LaBerge JM; Bensoussan AL; Blanchard H
Ann Chir; 1993; 47(9):803-9. PubMed ID: 8141543
[TBL] [Abstract][Full Text] [Related]
11. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.
Fällström SP; Lindblad B; Steen G
Acta Paediatr Scand; 1981; 70(3):315-20. PubMed ID: 7246125
[TBL] [Abstract][Full Text] [Related]
12. [Reference values of urinary delta-aminolevulinic acid in children].
Grisler R; Ferrari L; Ronco G; Rusconi R; Biella C; Carnelli V
Pediatr Med Chir; 1983; 5(3):87-9. PubMed ID: 6647070
[TBL] [Abstract][Full Text] [Related]
13. Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up.
Pierik LJ; van Spronsen FJ; Bijleveld CM; van Dael CM
J Inherit Metab Dis; 2005; 28(6):871-6. PubMed ID: 16435179
[TBL] [Abstract][Full Text] [Related]
14. Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation.
Tuchman M; Freese DK; Sharp HL; Ramnaraine ML; Ascher N; Bloomer JR
J Pediatr; 1987 Mar; 110(3):399-403. PubMed ID: 3546650
[TBL] [Abstract][Full Text] [Related]
15. Determination of urinary succinylacetone by capillary gas chromatography.
Tuchman M; Whitley CB; Ramnaraine ML; Bowers LD; Fregien KD; Krivit W
J Chromatogr Sci; 1984 May; 22(5):211-5. PubMed ID: 6725495
[TBL] [Abstract][Full Text] [Related]
16. [Determination of delta-aminolevulinic acid dehydratase in venous and capillary blood and delta-aminolevulinic acid in urine of lead-exposed workers].
Rothe R; Garlipp C
Arch Exp Veterinarmed; 1980; 34(3):361-5. PubMed ID: 7436670
[TBL] [Abstract][Full Text] [Related]
17. Succinylacetone inhibits delta-aminolevulinate dehydratase and potentiates the drug and steroid induction of delta-aminolevulinate synthase in liver.
Sassa S; Kappas A
Trans Assoc Am Physicians; 1982; 95():42-52. PubMed ID: 7182986
[TBL] [Abstract][Full Text] [Related]
18. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
[TBL] [Abstract][Full Text] [Related]
19. Succinylacetone and delta-aminolevulinic acid dehydratase in hereditary tyrosinemia: immunochemical study of the enzyme.
Sassa S; Fujita H; Kappas A
Pediatrics; 1990 Jul; 86(1):84-6. PubMed ID: 2359685
[TBL] [Abstract][Full Text] [Related]
20. Determination of urinary succinylacetone by capillary electrophoresis for the diagnosis of tyrosinemia type I.
Cansever MS; Erim FB
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Apr; 818(2):309-11. PubMed ID: 15734174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
